Karen Leander
Overview
Explore the profile of Karen Leander including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
380
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sweet K, Song Q, Loza M, McInnes I, Ma K, Leander K, et al.
RMD Open
. 2021 May;
7(2).
PMID: 34011674
Objective: To investigate serum protein expression in participants with psoriatic arthritis (PsA) and changes after guselkumab treatment. Methods: Participants with PsA were treated with guselkumab or placebo in the DISCOVER-1...
2.
Chornoguz O, Leettola C, Leander K, Brosnan K, Emmell E, Chiu M, et al.
Monoclon Antib Immunodiagn Immunother
. 2019 Dec;
38(6):242-254.
PMID: 31825302
Although CD3 T cell redirecting antibodies have been successfully utilized for the treatment of hematological malignancies (blinatumomab), the T cell signaling pathways induced by these molecules are incompletely understood. To...
3.
Sabins N, Chornoguz O, Leander K, Kaplan F, Carter R, Kinder M, et al.
J Immunol
. 2017 Nov;
199(12):4091-4102.
PMID: 29127145
T cell expression of TIM-3 following Ag encounter has been associated with a continuum of functional states ranging from effector memory T cells to exhaustion. We have designed an in...
4.
Metzger J, Tadin-Strapps M, Thankappan A, Strapps W, DiPietro M, Leander K, et al.
Thromb Haemost
. 2015 Mar;
113(6):1300-11.
PMID: 25790442
Haemophilia A and B are characterised by a life-long bleeding predisposition, and several lines of evidence suggest that risks of atherothrombotic events may also be reduced. Establishing a direct correlation...
5.
Proof-of-concept Studies for siRNA-mediated Gene Silencing for Coagulation Factors in Rat and Rabbit
Chen Z, Luo B, Cai T, Thankappan A, Xu Y, Wu W, et al.
Mol Ther Nucleic Acids
. 2015 Jan;
4:e224.
PMID: 25625614
The present study aimed at establishing feasibility of delivering short interfering RNA (siRNA) to target the coagulation cascade in rat and rabbit, two commonly used species for studying thrombosis and...
6.
Parmar R, Poslusney M, Busuek M, Williams J, Garbaccio R, Leander K, et al.
Bioconjug Chem
. 2014 Apr;
25(5):896-906.
PMID: 24742200
The application of small interfering (si)RNAs as potential therapeutic agents requires safe and effective methods for their delivery to the cytoplasm of the target cells and tissues. Recent studies have...
7.
Leander K, Berlin M, Eriksson A, Gadin K, Hensing G, Krantz G, et al.
Scand J Public Health
. 2012 Dec;
40(9 Suppl):229-54.
PMID: 23238410
No abstract available.
8.
Shi B, Keough E, Matter A, Leander K, Young S, Carlini E, et al.
J Histochem Cytochem
. 2011 Aug;
59(8):727-40.
PMID: 21804077
Chemically stabilized small interfering RNA (siRNA) can be delivered systemically by intravenous injection of lipid nanoparticles (LNPs) in rodents and primates. The biodistribution and kinetics of LNP-siRNA delivery in mice...
9.
Cherrin C, Haskell K, Howell B, Jones R, Leander K, Robinson R, et al.
Cancer Biol Ther
. 2010 Feb;
9(7):493-503.
PMID: 20139722
The PI3K-Akt pathway is dysregulated in the majority of solid tumors. Pharmacological inhibition of Akt is a promising strategy for treating tumors resistant to growth factor receptor antagonists due to...
10.
Li Y, Liang J, Siu T, Hu E, Rossi M, Barnett S, et al.
Bioorg Med Chem Lett
. 2008 Dec;
19(3):834-6.
PMID: 19097777
A series of [1,2,4]triazolo[3,4-f][1,6]naphthyridine allosteric dual inhibitors of Akt1 and 2 have been developed. These compounds have been shown to have potent dual Akt1 and 2 cell potency. The representative...